-
癌症是全球第二大死因,尽管癌症发生的确切原因尚不清楚,但早期的检测和治疗却能够改善患者的生活质量并延长其生命。因此,早期诊断肿瘤并制定合适的治疗方案就显得极为关键[1]。放射性核素显像是肿瘤早期的诊断方法之一,目前能够为临床提供极富参考价值的分子和肿瘤生物学显像技术尚未较好地发现或建立,已应用于临床的基于肿瘤对葡萄糖高摄取的18F-FDG PET显像虽具备肿瘤高灵敏度,但却存在一定的假阳性率和假阴性率的问题,例如,炎症反应也会引起其聚集[2]。放射性核素显像对于肿瘤的应用前景除显像设备外,另一个重要方面是有待于新型的、特异性更高的显像剂的开发,问题的关键在于如何设计出具备肿瘤摄取高、背景低、血液清除迅速的肿瘤放射性靶向药物。本文对目前备受关注且正处于广泛研究阶段的肿瘤新生血管整合素αvβ3受体显像进行综述。
靶向肿瘤新生血管整合素αvβ3受体显像研究现状及进展
Progress on tumor angiogenesis imaging targeting integrin αvβ3 receptor
-
摘要: 恶性肿瘤的生长和转移依赖于肿瘤血管新生,研究发现整合素αvβ3高表达于肿瘤新生血管内皮细胞和部分肿瘤细胞表面,可通过介导细胞粘附来调控肿瘤血管新生,而整合素αvβ3在正常血管和组织表面不表达或呈低水平表达,据此可将其用作肿瘤新生血管显像和治疗的新靶点。近年来国内外关于整合素αvβ3靶向药物的设计、放射性核素的选择以及此类药物的最新研究内容有了较大进展,笔者将对如何更好地设计整合素αvβ3靶向药物、选择合适的放射性核素以及此类药物的研究方向进行综述。
-
关键词:
- 新生血管化, 病理性 /
- 整合素αvβ3 /
- 放射性核素显像
Abstract: Malignant tumors′ growth and metastasis depend on tumor angiogenesis. Recent studies had found that the integrin αvβ3 had a high expression on the surface of tumor angiogenesis endothelial cells and parts of the tumor cells, it can regulate tumor angiogenesis by cell adhesion, but it does not express on the surface of normal blood vessels or the normal organizations, or only had a low level expression. Thus it can be used as a new target for the tumor angiogenesis imaging and treatment. Recent years, there is a great progress on the design of the integrin αvβ3 targeting agents, the selection of radionuclides, and the latest research on the agents at home and abroad. This article will made a review on how to better design the integrin αvβ3 agents, choose the appropriate radionuclides, and the research direction of these agents.-
Key words:
- Neovascularization, pathologic /
- Integrin αvβ3 /
- Radionuclide imaging
-
[1] Liu S. Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency[J]. Bioconjug Chem, 2009, 20(12): 2199-2213. doi: 10.1021/bc900167c [2] Herrmann K, Erkan M, Dobritz M, et al. Comparison of 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography(FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5): 846-851. doi: 10.1007/s00259-012-2061-8 [3] Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl Med, 1971, 285(21): 1182-1186. doi: 10.1056/NEJM197111182852108 [4] Hu XD, Xing LG, Yu JM. Nuclear medical molecular imaging of tumor angiogenesis: current status and future prospects[J]. Chin Med J(Engl), 2013, 126(14): 2741-2746. [5] 刘开元, 李前伟, 刘广元.放射性标记RGD序列多肽与整合素αvβ3受体显像的研究进展[J].医学综述, 2006, 12(12): 757-759. doi: 10.3969/j.issn.1006-2084.2006.12.023
[6] Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas[J]. Int J Cancer, 1997, 71(3): 320-324. doi: 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-# [7] 王浩, 施培基, 周晓靓, 等. RGD肽及其衍生物在肿瘤显像剂治疗中的研究进展[J].国际放射医学核医学杂志, 2007, 31(5): 274-277. doi: 10.3760/cma.j.issn.1673-4114.2007.05.006
[8] 邵国强, 王自正.整合素αvβ3受体靶向肿瘤显像研究进展[J].国际放射医学核医学杂志, 2014, 38(1): 33-36.
[9] Yu YP, Wang Q, Liu YC, et al. Molecular basis for the targeted binding of RGD-containing peptide to integrin alphaVbeta3[J]. Biomaterials, 2014, 35(5): 1667-1675. doi: 10.1016/j.biomaterials.2013.10.072 [10] Alam IS, Witney TH, Tomasi G, et al. Radiolabeled RGD Tracer Kinetics Annotates Differential αvβ3 Integrin Expression Linked to Cell Intrinsic and Vessel Expression[J/OL]. Mol Imaging Biol, 2013[2014-03-20]. http://link.springer.com/article/10.1007%2Fs11307-013-0710-3. [published online ahead of print Dec 6, 2013]. [11] Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C, et al. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors[J]. Nucl Med Biol, 2014, 41(3): 259-267. [12] Maschauer S, Haubner R, Kuwert T, et al. 18F-Glyco-RGD Peptides for PET Imaging of Integrin Expression: Efficient Radiosynthesis by Click Chemistry and Modulation of Biodistribution by Glycosylation[J]. Mol Pharm, 2014, 11(2): 505-515. doi: 10.1021/mp4004817 [13] Jin ZH, Furukawa T, Sogawa C, et al. PET imaging and biodistribution analysis of the effects of succinylated gelatin combined with L-lysine on renal uptake and retention of Cu-cyclam-RAFT-c(-RGDfK-)in vivo[J]. Eur J Pharm Biopharm, 2013, 86(3): 478-486. [14] Liu ZF, Niu G, Shi J, et al. 68Ga-labeled cyclic RGD dimmers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 947-957. doi: 10.1007/s00259-008-1045-1 [15] Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases[J]. Molecules, 2013, 18(3): 3379-3409. doi: 10.3390/molecules18033379 [16] Lewis MR, Kao JY, Anderson AL, el al. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA[J]. Bioconjug Chem, 2001, 12(2): 320-324. doi: 10.1021/bc0000886 [17] Zhang Y, Hong H, Engle JW, et al. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA[J/OL]. PloS One, 2011, 6(12): e28005[2014-03-20]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028005. [18] Yapp DT, Ferreira CL, Gill RK, et al. Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA[J]. Mol Imaging, 2013, 12(4): 263-272. [19] 王荣福, 李险峰, 王强. SPECT/CT的最新应用进展[J]. CT理论与应用研究, 2012, 21(3): 577-582.
[20] 张春丽, 杨铭, 王荣福. RGD肽与整合素αvβ3受体结合的构效关系及放射性标记配体的设计[J].肿瘤学杂志, 2009, 15(1): 76-81.
[21] Beer A J, Lorenzen S, Metz S, et al. Comparison of integrin αVβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG[J]. J Nucl Med, 2008, 49(1): 22-29. [22] Sugiura G, Kuhn H, Sauter M, et al. Radiolabeling strategies for tumor-targeting proteinaceous drugs[J]. Molecules, 2014, 19(2): 2135-2165. doi: 10.3390/molecules19022135 [23] Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study[J]. Ann Rheum Dis, 2014, 73(6): 1269-1272. doi: 10.1136/annrheumdis-2013-204820 [24] Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, et al. Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer[J]. J Nucl Med, 2014, 55(3): 446-451. [25] Durkan K, Jiang Z, Rold T L, et al. A heterodimeric[RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors[J]. Nucl Med Biol, 2014, 41(2): 133-139. [26] Shallal HM, Minn I, Banerjee SR, et al. Heterobivalent agents targeting PSMA and integrin-αvβ3[J]. Bioconjug Chem, 2014, 25(2): 393-405. doi: 10.1021/bc4005377 [27] Rangger C, Helbok A, Sosabowski J, et al. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles[J]. Int J Nanomedicine, 2013, 8: 4659-4671. [28] Debergh I, Van Damme N, De Naeyer D, et al. Molecular imaging of tumor-associated angiogenesis using a novel magnetic resonance imaging contrast agent targeting alphabeta integrin[J]. Ann Surg Oncol, 2013, 21(6): 2097-2104. [29] Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3PI4-RGDF scintigraphy[J]. Eur J Nucl Med Mol Imaging, 2011, 38(12): 2145-2152. doi: 10.1007/s00259-011-1901-2 [30] Zhao D, Jin X, Li F, et al. Integrin αvβ3 Imaging of Radioactive Iodine-Refractory Thyroid Cancer Using 99mTc-3PRGD2[J]. J Nucl Med, 2012, 53(12): 1872-1877. doi: 10.2967/jnumed.112.107821 [31] Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study[J]. J Nucl Med, 2012, 53(5): 716-722. doi: 10.2967/jnumed.111.098988 [32] Shi J, Fan D, Dong C, et al. Anti-tumor effect of integrin targeted 177Lu-3PRGD2 and combined therapy with endostar[J]. Theranostics, 2014, 4(3): 256-266. doi: 10.7150/thno.7781 [33] 贺欣, 赵启仁, 宋娜玲, 等.肿瘤抑素T7肽及其衍生物T7-NGR载体构建及表达[J].生物工程, 2008, 12(3): 240-244.
[34] 郝玉美, 贺欣, 周晓靓, 等. 99mTc标记T7肽及其在裸鼠非小细胞肺癌模型体内的生物分布研究[J].中国肺癌杂志, 2014, 17(3): 189-196.
计量
- 文章访问数: 2844
- HTML全文浏览量: 1713
- PDF下载量: 8